Join to access to all OVN content. Join for Free
Diversity in Medical Affairs and the Power of Networking
networking in medical affairs DEMA mission career advancement tips medical affairs professionals diversity in medical affairs

Diversity in Medical Affairs and the Power of Networking


Share This Article


Summary

In this episode, Tom Caravela welcomes guests Rachel Kennedy, Lashondra Taylor, and Nirav Shah to discuss the formation and mission of DEMA. They explore the transformative power of networking, sharing Rachel's inspiration behind DEMA and how to engage with the organization. The conversation includes networking success stories and valuable advice for new MSLs and job seekers. The guests outline DEMA's current initiatives and future plans, highlighting upcoming events. The episode concludes with updates from Tom and expressions of appreciation for the listeners' support.

My guests today are Rachel Kennedy, LaShaundra Taylor, and Nirav Shah from DiMA (Diversity in Medical Affairs) and we discuss the story of DiMA and the power of networking.

In this episode we discuss:

  • Intro of Rachel, LaShaundra, and Nirav
  • The story of how the DiMA group was formed
  • What is the mission and how can people join or get involved?
  • Their advice for medical affairs professionals on networking and how it can advance their career
  • Examples of how networking has helped them in their careers.
  • Other advice to those that are looking to build a career in Medical Affairs

Click for Source
networking in medical affairs, DEMA mission, career advancement tips, medical affairs professionals, diversity in medical affairs

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Fierce Pharma Engage 2025 - RECAP
Partner Avatar MSL Talk: Tom Caravela, Patrina Pellett

Fierce Pharma Engage 2025 - RECAP

Podcast
Time Audit: YOUR Strategy for Time Management Success
Partner Avatar MSL Talk: Tom Caravela, Patrina Pellett

Time Audit: YOUR Strategy for Time Management Success

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN